1 Complex Patient Perspectives on Evolving Diverticulitis Treatment

3 Patient Perspectives on Diverticulitis

- 5 Annie Altman-Merino BS^1 , Kemberlee Bonnet, MA^2 , David Schlundt PhD², Jessie Wrenn, MD,
- PhD^{3,4}, Wesley H. Self, MD, MPH⁵, Elisa J. Gordon PhD, MPH⁶, Alexander T. Hawkins MD,
 MPH⁷
- 8

2

- 9 ¹School of Medicine, Vanderbilt University, Nashville, TN
- 10 ²Department of Psychology, Vanderbilt University, Nashville, TN
- ³Vanderbilt University Medical Center, Department of Emergency Medicine, Nashville, TN
- 12 ⁴Vanderbilt University Medical Center Department of Biomedical Informatics, Nashville, TN
- ⁵ Vanderbilt University Medical Center, Vanderbilt Institute for Clinical and Translational
- 14 Research and Department of Emergency Medicine, Nashville, TN
- ⁶Vanderbilt University Medical Center, Department of Surgery, and Center for Biomedical
- 16 Ethics and Society, Nashville, TN.
- ⁷Vanderbilt University Medical Center, Division of General Surgery, Section of Colon & Rectal
- 18 Surgery, Nashville, TN.
- 19
- 20 Address for correspondence:
- 21 Alexander T Hawkins, MD, MPH
- 22 Section of Colon & Rectal Surgery
- 23 Vanderbilt University
- 24 1161 21st Ave South
- 25 Room D5248 MCN
- 26 Nashville, TN 37232
- 27 Office: 615.343.4612
- 28 Fax: 615.343.4615
- 29 Email: alex.hawkins at vumc.org
- 30
- 31 Email correspondence for all authors:
- 32 Anne.e.altman-merino@vanderbilt.edu; Kemberlee.bonnet@vanderbilt.edu;
- 33 David.schlundt@vanderbilt.edu; Jesse.wrenn.1@vumc.org; Welsey.self@vumc.org;
- 34 Elisa.gordon@vumc.org
- 35
- 36 Conflicts of Interest: None
- 37
- Funding: Dr Hawkins' work on this manuscript was supported by the National Institute of
- 39 Diabetes and Digestive and Kidney Disease of the National Institutes of Health under award
- 40 number K23DK118192. The Vanderbilt Institute for Clinical and Translational Research
- 41 (VICTR) is funded by the National Center for Advancing Translational Sciences (NCATS)
- 42 Clinical Translational Science Award (CTSA) Program, Award Number 5UL1TR002243-03
- 43 (Voucher V0000039202). The content is solely the responsibility of the authors and does not
- 44 necessarily represent the official views of the National Institutes of Health.
- 45
- 46 Text word count: 29921/3000 words

47 Abstract word count: 299/300

- 48
- 49 Author contribution:
- 50 AAM designed and executed all study procedures including manuscript drafting and editing. KB
- 51 assisted interview guide design, qualitative training of primary author, and manuscript writing.
- 52 DS supported qualitative analysis including writing of the corresponding manuscript section. JW
- and WHS assisted with interviewee identification through the emergency department and
- 54 contributed to writing and editing. EG supported qualitative analysis and contributed to writing
- and editing. ATH oversaw all study procedures and contributed to writing and editing. All
- 56 authors reviewed the final manuscript.
- 57
- 58 Category: Benign colorectal disease
- 59

60 Abstract

61 Background: Despite evidence that antibiotics may not be necessary to treat acute uncomplicated 62 diverticulitis, they remain the mainstay of treatment in the United States. A randomized 63 controlled trial evaluating antibiotic effectiveness could accelerate implementation of an 64 antibiotic-free treatment strategy, but patients may be unwilling to participate. 65 Objective: This study aims to assess patients' attitudes regarding participation in a randomized 66 trial of antibiotics versus placebo for acute diverticulitis, including willingness to participate. 67 Design: This is a mixed-methods study with qualitative and descriptive methods. 68 Settings: Interviews were conducted in a quaternary care emergency department and surveys 69 were administered virtually through a web-based portal. 70 Patients: Patients with either current or previous acute uncomplicated diverticulitis participated. 71 Interventions: Patients underwent semi-structured interviews or completed a web-based survey. 72 Main Outcome measures: Rates of willingness to participate in a randomized controlled trial was 73 measured. Salient factors related to healthcare decision-making were also identified and 74 analyzed. 75 Results: Thirteen patients completed an interview. Reasons to participate included a desire to 76 help others or contribute to scientific knowledge. Doubts about the efficacy of observation as a 77 treatment method were the main barrier to participation. In a survey of 218 subjects, 62% of 78 respondents reported willingness to participate in a randomized clinical trial. "What my doctor 79 thinks," followed by "What I've experienced in the past" were the most important decision-80 making factors.

82	Limitations: There is possible selection bias inherent to using a study to evaluate willingness to
83	participate in a study. Also, the population sampled was disproportionately White compared to
84	the population affected by diverticulitis.
85	
86	Conclusions: Patients with acute uncomplicated diverticulitis maintain complex and varying
87	perceptions of the use of antibiotics. Most surveyed patients would be willing to participate in a
88	trial of antibiotics versus placebo. Our findings support a trial's feasibility and facilitate an
89	informed approach to recruitment and consent.
90	
91	Key Words: diverticulitis, diverticular disease, patient perspectives, qualitative analysis,
92	antibiotic stewardship
93	

94 Introduction:

Diverticular disease is one of the most prevalent conditions in the United States, and its
incidence is increasing. Acute diverticulitis is a leading cause of emergency department (ED)
visits, accounting for over 360,000 visits per year¹. Despite evidence that antibiotics are not
necessary to treat acute uncomplicated diverticulitis (AUD)²⁻⁴ and models of diverticulitis
pathophysiology suggesting an inflammatory process rather than an infectious one^{5,6}, antibiotics
remain the mainstay of treatment in the US.

101 Unnecessary use of antibiotics is harmful. Antibiotic misuse exacerbates antibiotic 102 resistance, accounting for more dangerous infections and difficult-to-eradicate pathogens. In the 103 US, over 2.8 million antibiotic-resistant infections develop per year, resulting in over 35,000 associated deaths⁷. Overuse of antibiotics leads to longer hospital stays, more readmissions, and 104 ultimately higher mortality rates due to infectious disease⁸. Antimicrobial resistance due to 105 overuse carries a high economic burden of \$55 billion per year in the US⁷. Management of 106 107 uncomplicated diverticulitis without antibiotics represents an opportunity to educate prescribers 108 and reduce antibiotic prescriptions for one of the leading causes of ED visits in the US. 109 Despite this, antibiotics remain the standard treatment in the US. Three randomized 110 controlled trials in Europe have demonstrated non-inferiority of symptomatic and supportive care 111 without antibiotics compared to treatment with antibiotics for the outcomes of perforation and abscess formation, median hospital stay, and diverticulitis reccurance²⁻⁴. Guidelines from the 112 American Gastroenterological Association, American Society of Colon and Rectal Surgeons, and 113 114 American College of Physicians state that uncomplicated cases can be treated without antibiotics⁹⁻¹². The reasons for continued antibiotic use are multifactorial, including lack of 115 116 physician awareness of updated literature and guidelines, physician fear of medicolegal

consequences of "observation," and patient expectation of treatment with antibiotics¹³. However, 117 118 the threat of antibiotic resistance is genuine, and continued inappropriate use of antibiotics is 119 antithetical to a rigorous effort to curtail resistance. 120 A North American randomized controlled trial of antibiotics versus no antibiotics for 121 AUD that demonstrated non-inferiority of an antibiotic-free approach would likely help decrease superfluous antimicrobial use for uncomplicated diverticulitis¹³. This study aims to assess 122 123 patients' perceptions and attitudes regarding participation in a randomized controlled trial of 124 antibiotics versus no antibiotics for AUD and evaluate willingness to participate in such a trial. 125 126 **Materials and Methods:** 127 This mixed-methods study assessed patient perspectives through focused interviews 128 followed by a survey of a separate, larger cohort to quantify themes that emerged from the

interviews. Vanderbilt University Medical Center Institutional Review Board approved this
study with allowance of verbal consent for the focused interviews (IRB #2210530) and a waiver

131 of informed consent for surveys (IRB #221611).

132

133 Focused Interviews

Semi-structured interviews were conducted both in-person in the Vanderbilt University
(VUMC) ED and over the phone. Individuals eligible to participate in in-person interviews
included adult (age 18-90 years), English-speaking patients presenting to the VUMC ED with
AUD and adequate cognitive capacity to participate. Exclusion criteria for this group included
complicated diverticulitis such as bleeding, abscess, or perforation; asymptomatic diverticulitis
found incidentally on CT scan; history of colon or rectal cancer, Crohn's disease, or ulcerative

colitis; end-stage renal disease; or previous colectomy. Individuals eligible to participate in
phone interviews included adult English-speaking patients with a history of AUD treated at
VUMC. Interviews were conducted from October 2022 to December 2022. Once the study team
recognized that no novel themes emerged during interviews, it was determined that thematic
saturation was reached, and the survey phase concluded¹⁴.

The interview guide was created with support from the VUMC Qualitative Research
Core¹⁵. It was designed to allow patients to reflect on their expectations, experiences and
opinions about diverticulitis using four open-ended questions followed by four focused questions
to obtain thoughts about side effects of antibiotics, antibiotic resistance, and treatment guidelines
(Full interview guide Supplemental Material 1).

150 Subjects were identified using natural language processing of radiologists' interpretations of computed tomography (CT) scans to identify Unified Medical Language System concepts 151 152 representing diverticulitis. Study personnel were sent an email alert within minutes of radiology 153 interpretation and reviewed the CT scan, radiology interpretation, and patient chart to ensure 154 eligibility. The interviewer (AAM), a female medical student who underwent qualitative 155 interview training with the Qualitative Research Core, approached eligible participants and obtained verbal consent for participation. The interviewer had no prior relationship to patients 156 157 and disclosed that she is a medical student with interest in the research topic. Interviewees were 158 not compensated. Interviews were recorded using a Sony ICD-PX370 digital voice recorder. 159 Phone interview participants were identified through an electronic medical record query of 160 patients seen in the VUMC Colon and Rectal Surgery Clinic. The interviewer called participants 161 and obtained verbal consent for participation.

163 <u>Qualitative Analysis</u>

164	Audio recordings of interviews were transcribed using an online transcription service
165	(https://rev.com) and transcripts were verified manually and not shared with participants. Coding
166	and thematic analysis were conducted by AAM. Interview content was analyzed using open
167	coding and thematic analysis. According to the grounded theory approach, theories were derived
168	from raw data by generating and applying codes ¹⁶ . The first five transcripts were reviewed, and
169	each line of text was ascribed one or more codes which were derived inductively from the data.
170	After review of the first five transcripts, codes were distilled into a codebook which was
171	referenced to code the remaining transcripts. Thematic analysis was conducted through four
172	steps of qualitative analysis identified by Green et al - immersion in the data, coding, creating
173	categories, and identification of themes ¹⁷ . Qualitative data collection and analysis were
174	performed in accordance with the Standards for Reporting Qualitative Research ¹⁸ .
175	
175 176	Survey Methodology
176	Survey Methodology
176 177	<u>Survey Methodology</u> Qualitative analysis of interview data informed the development of a web-based survey to
176 177 178	<u>Survey Methodology</u> Qualitative analysis of interview data informed the development of a web-based survey to quantify attitudes and beliefs of a separate, larger cohort. Individuals eligible to participate in
176 177 178 179	Survey Methodology Qualitative analysis of interview data informed the development of a web-based survey to quantify attitudes and beliefs of a separate, larger cohort. Individuals eligible to participate in surveys included patients with a history of diverticulitis. Exclusion criteria were a history of
176 177 178 179 180	Survey Methodology Qualitative analysis of interview data informed the development of a web-based survey to quantify attitudes and beliefs of a separate, larger cohort. Individuals eligible to participate in surveys included patients with a history of diverticulitis. Exclusion criteria were a history of colon and rectal cancer, Crohn's disease or ulcerative colitis, end-stage renal disease, or previous

184 three sections, each with five items that participants were asked to rank from least important to 185 most important. The survey was reviewed and revised by the research team and beta tested by

both physicians and patients. It was distributed as an online survey using REDCap¹⁹. Additional 186 187 free text items asked participants to describe their reasons for being willing or unwilling to 188 participate in a randomized clinical trial. (Supplemental Material 2). 189 Survey participants were identified using social media, VUMC's electronic health record 190 (EHR), and ResearchMatch, a national health volunteer registry supported by the US National 191 Institutes of Health as part of the Clinical Translational Science Award program. An IRB-192 approved recruitment message was posted on diverticulitis-related social media pages and sent to 193 eligible ResearchMatch volunteers (Supplemental Materials 3). Eligible participants identified 194 via ICD-10 codes through the EHR were contacted with an IRB-approved message through My 195 Health at Vanderbilt, VUMC's patient health portal. Participants were given the option to enter a 196 raffle to win a \$100 gift certificate upon completion of the survey. Participants were screened for 197 eligibility through a REDCap survey and given access to the study survey if they met eligibility. 198 199 Survey Data Analysis 200 Descriptive statistics were performed to examine frequencies, means, and standard 201 deviations in survey data. Ranked factors were viewed by number of times ranked "most 202 important" and number of times ranked "least important." Qualitative analysis was applied to 203 participants' explanations of willingness or unwillingness to participate with an open coding and 204 thematic analysis approach similar to the methods described in the focused interview section. 205 206 **Results**

207 <u>Participant Characteristics</u>

208	Thirteen patients completed an interview: nine in the ED with an episode of AUD and
209	four over the phone without a current episode (100% participation for in-person interviews, 67%
210	for phone interviews). All were interviewed alone and only once. Most participants were female
211	(62%, n=8/13) and non-Hispanic White $(85%, n=11/13)$. Detailed patient characteristics are
212	presented in Table 1. Participants had a mean age of 62 years. Mean interview duration was 16
213	minutes (SD 6 minutes).

214

215 <u>Themes</u>

216 Two salient themes that emerged were sources of information used in decision making 217 and factors contributing to reluctance or desire to participate in a trial. Information sources 218 guiding the decision-making process included personal experiences along with provider 219 recommendations. Patients reporting reluctance to participate in a trial commonly expressed 220 doubts about the efficacy of observation as a treatment strategy. Themes regarding willingness to 221 participate were desire to avoid antibiotics in the future, to help others, and to contribute to 222 public knowledge. Figure 1 demonstrates a conceptual model of factors contributing to 223 reluctance or desire to participate. Table 2 includes quotations illustrating each of these themes. 224

225 <u>Sub-Theme 1: Personal History and Experiences</u>

Participants referenced personal experiences of disease episodes when considering
participation in a trial and chronicled a recurring sequence of events: diagnosis of diverticulitis,
antibiotic administration, and subsequent symptom resolution. Recognizing and reflecting on the
pattern of symptom resolution after antibiotics influenced how participants considered

230 participation in a trial where they may not receive antibiotics.

231	
232	So to be honest, it seems that from my experience, and I know it's anecdotal, it
233	seems [to] suggest there was a physiological change from the medication.
234	(Participant 2)
235	
236	Participant 2 reflected on his past experiences, and by the end of the discussion, had
237	drawn upon them to reach a decision:
238	
239	Well, talking it out, it's kind of helped me process and see that from a very first
240	episode, it seems like the amoxicillin was effective So actually, just talking to
241	you, I started to lean more towards staying with amoxicillin. (Participant 2)
242	
243	Patients' perceptions of antibiotic efficacy in the past, whether perceived as high or low efficacy,
244	informed decisions about participation in a trial. This individual perceived that antibiotics were
245	effective during previous episodes, which precipitated reluctance to participate in a trial. Given
246	the recurring and episodic nature of diverticular disease, personal experience is particularly
247	salient to decisions about disease management.
248	
249	Sub-Theme 2: Influence of Providers on Participant Perceptions
250	Participants considered providers' recommendations about whether antibiotics would be
251	beneficial as central to their perceptions of diverticulitis treatment. Some participants identified
252	their individual primary care provider or the ED provider as trusted sources of guidance about
253	treatment options.

254	
255	I think I would need to talk to my doctor, my family doctor. I think that would be
256	my best bet. (Participant A)
257	
258	Others invoked the authority of providers as a collective medical community who have accepted
259	antibiotics as the standard treatment.
260	
261	You just trust the science or whatever it doesn't matter which doctor,
262	everybody prescribes the antibiotic regardless So I've never questioned it
263	because that's what they say it takes. (Participant 5)
264	
265	Sub-Theme 3: Observation Hesitancy
266	Most participants who were unwilling to participate in a trial doubted the efficacy of
267	observation as a treatment strategy, believing that antibiotics are necessary for recovery. These
268	participants tended to view the omission of antibiotics as the omission of treatment.
269	
270	At least when I have it, I mean, I can't imagine if there was no treatment, because
271	I've had to wait before to get treatment and it didn't get any better. (Participant 6)
272	
273	The interviewer informed participants that the placebo arm would receive treatment in the
274	form of supportive care, pain control, and close observation. However, some participants
275	interpreted the lack of antibiotics as "no treatment."
276	

277	So if I'm getting the sugar pill then I'm in the control group, does that mean I'm
278	not getting any treatment at all? (Participant B)
279	
280	Sub-Theme 4: Desire to Avoid Antibiotics in the Future
281	Aversion towards antibiotics contributed to both reluctance and desire to participate.
282	Some patients feared placement in the antibiotic study group and others saw participation in the
283	study as a means of avoiding antibiotics in the future.
284	
285	But I never take an antibiotic unless I have to. I just am afraid it would - you take
286	too many and it won't work. (Participant C)
287	
288	Concern about taking any medication and aversion to unnecessary medical treatment in general
289	were commonly shared sentiments.
290	
291	Well, I think that people get over-medicated sometimes, I do. (Participant 4)
292	
293	Sub-Theme 5: Helping Others and Advancing Public Knowledge
294	The public impact of study participation, including advancing public knowledge and
295	helping others, were primary drivers of patients' willingness to participate.
296	
297	I struggle with this for 10 years and any advancement in the treatment, I'd be glad
298	to be part of that. Yeah, it would help a lot of people, I would think. (Participant
299	2)

301 <u>Survey Quantitative Results</u>

302	Two hundred and eighteen participants completed the survey. Participation rate by
303	method is demonstrated in Figure 2. Mean participant age was 57.9 years (SD 13.3 years), and
304	most were female (61.9%), and non-Hispanic White (69.7%). Detailed patient characteristics are
305	presented in Table 3.
306	One Hundred and thirty-five respondents (62%) reported willingness to participate in a
307	trial of antibiotics versus placebo during an episode of AUD. Figure 3 illustrates the number of
308	times each factor was ranked most important. The two leading reasons to participate included
309	"Helping make guidelines for treatment better" (48%) and "Avoiding antibiotics" (22%).
310	When prompted to rank the importance of various factors used to make healthcare
311	decisions, the leading factors were "What my doctor thinks," (56%) and "What I've experienced
312	in the past" (36%). Only 5% reported "What the doctor seeing me in the Emergency Department
313	thinks" as most important. "Needing an ostomy bag" was the most feared outcome of
314	diverticulitis (55%).
315	
316	Qualitative Results of Surveys
317	Among 83 who reported unwillingness to participate, 67 explained their response. These
318	explanations largely fall into two categories: fear of an antibiotic-free treatment and aversion to
319	antibiotics themselves.

I have had diverticulitis three times and each time it was cleared up with

antibiotics. The thought of getting a placebo scares me. (Male in their 60s)

323	
324	Fear of not receiving antibiotics contrasts with preference for a non-antibiotic strategy.
325	
326	Don't trust antibiotics. Makes it worse. Longer to heal. (Male in their 60s)
327	
328	Those who were willing to participate specified a desire to help others, contribute to
329	diverticulitis-related research, or understand the disease themselves.
330	
331	I like to help and would like a better understanding of diverticulitis. (Female in their 40s)
332	
333	Discussion and Conclusions
334	. Considering that patient hesitancy to participate in a trial of antibiotics versus placebo
335	has been a major barrier to its execution, understanding patients' opinions is essential to
336	conducting a trial and ultimately implementing a change in the standard treatment of
337	diverticulitis. Both qualitative literature and literature regarding patient perspectives are
338	increasingly recognized as important for informing treatment strategies and understanding trial
339	recruitment ^{14, 20-22} . This mixed-methods study assessed patients' perceptions of diverticulitis
340	treatment options through semi-structured interviews with patients in addition to a survey of a
341	larger cohort, and found that most patients with a history of diverticulitis report willingness to
342	participate in a trial of antibiotics versus placebo for AUD. It also identified factors that patients
343	consider when making decisions related to their healthcare, with their doctor's recommendation
344	being the most important.

345 Over 60% of survey respondents reported willingness to participate in a trial of 346 antibiotics versus placebo for AUD. This enthusiasm for trial participation would support robust 347 enrollment in an actual trial and scientific integrity. Our findings support the feasibility of such a 348 trial and can be applied during its planning and execution to facilitate patient-centeredness in 349 methods and analysis. This number is especially encouraging when compared to participation 350 rates in similar US surgical trials that have recruited from the ED. For example, the CODA trial, 351 comparing antibiotics with appendectomy for appendicitis, had a 31% enrollment rate among 352 eligible patients²³.

Confidence in providers was evident in conversations with patients and survey responses. ED provider opinions carried weight particularly in interviews, where these providers were the first to communicate diagnoses and present treatment options. Interviewees also expressed confidence in doctors and the medical community to make the best decision for them. These findings highlight the potential for providers to affect patient perspectives on the use of an antibiotic-free strategy.

A key strength of this study is that interviews simulated enrollment in an RCT: most patients were recruited in the ED at the time of diagnosis, before either discharge or hospital admission. This recruitment approach provided a unique view into patient perceptions of treatment options at the time that they would be enrolled, and therefore reflected authentic concerns, doubts, and questions that typically arise in that context.

Our study has limitations. There is the possibility of selection bias, which is inherent to conducting a study to evaluate willingness to participate in a study. However, all individuals approached in-person in the ED agreed to participate in an interview, indicating that the population was not skewed towards those who are more inclined to participate. The population

368	sampled was disproportionately White compared to the population affected by diverticulitis,
369	meaning that the perspectives of some voices underrepresented in biomedical research are left
370	out. Another limitation was that survey respondents did not have the opportunity to engage in
371	dynamic discussion with the research team. Some participants misunderstood the explanation of
372	the trial and indicated unwillingness to undergo randomization because they were not currently
373	experiencing symptoms. Consequently, participants' willingness may have been underestimated.
374	In conclusion, the most important factors guiding patients' decision making about
375	diverticulitis treatment include recommendations by trusted providers and perceptions of
376	observation as ineffective treatment. These factors may be modulated over time as providers
377	accept an antibiotic-free approach and affirm its legitimacy to patients. A US-based randomized
378	controlled trial of antibiotics versus placebo for acute uncomplicated diverticulitis is feasible in
379	terms of patient recruitment, and even anticipated by patients.
380	
381	Acknowledgements
382 383	We thank Dario Giuse, Dr. Ing, MS, FACMI, for his contribution to the study.
384 385	References
296	1 Dollars A Austria I Himsh W at al Engeneer au deportment hunder of divertioulitie in
386	1. Bollom A, Austrie J, Hirsch W, et al. Emergency department burden of diverticulitis in
387	the USA, 2006-2013. Dig Dis Sci. 2017;62:2694–2703.

- 2. Chabok A, Påhlman L, Hjern F, Haapaniemi S, Smedh K; AVOD Study Group.
- 389 Randomized clinical trial of antibiotics in acute uncomplicated diverticulitis. *Br J Surg*.
- **390** 2012;99(4):532-539. doi:10.1002/bjs.8688

391	3.	Daniels L, Ünlü Ç, de Korte N, et al. Randomized clinical trial of observational versus
392		antibiotic treatment for a first episode of CT-proven uncomplicated acute
393		diverticulitis. Br J Surg. 2017;104(1):52-61. doi:10.1002/bjs.10309
394	4.	Mora-López L, Ruiz-Edo N, Estrada-Ferrer O, et al. Efficacy and Safety of Nonantibiotic
395		Outpatient Treatment in Mild Acute Diverticulitis (DINAMO-study): A Multicentre,
396		Randomised, Open-label, Noninferiority Trial. Ann Surg. 2021;274(5):e435-e442.
397		doi:10.1097/SLA.0000000000005031
398	5.	Piscopo N, Ellul P. Diverticular Disease: A Review on Pathophysiology and Recent
399		Evidence. Ulster Med J. 2020;89(2):83-88.
400	6.	Zullo A. Medical hypothesis: speculating on the pathogenesis of acute diverticulitis. Ann
401		Gastroenterol. 2018;31(6):747-749.
402	7.	Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United
403		States. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-
404		<u>508.pdf</u> . 2019.
405	8.	Dadgostar P. Antimicrobial Resistance: Implications and Costs. Infect Drug Resist.
406		2019;12:3903-3910. Published 2019 Dec 20. doi:10.2147/IDR.S234610Dadgostar P.
407		Antimicrobial Resistance: Implications and Costs. Infect Drug Resist. 2019;12:3903-
408		3910. Published 2019 Dec 20. doi:10.2147/IDR.S234610
409	9.	Peery AF, Shaukat A, Strate LL. AGA Clinical Practice Update on Medical Management
410		of Colonic Diverticulitis: Expert Review. Gastroenterology. 2021;160(3):906-911.e1.
411		doi:10.1053/j.gastro.2020.09.059
412	10.	. Stollman N, Smalley W, Hirano I; AGA Institute Clinical Guidelines Committee.
413		American Gastroenterological Association Institute Guideline on the Management of

414 Acute Diverticulitis. *Gastroenterology*. 2015;149(7):1944-1949.

- 415 doi:10.1053/j.gastro.2015.10.003
- 416 11. Hall J, Hardiman K, Lee S, et al. The American Society of Colon and Rectal Surgeons
- 417 Clinical Practice Guidelines for the Treatment of Left-Sided Colonic Diverticulitis. *Dis*

418 *Colon Rectum*. 2020;63(6):728-747. doi:10.1097/DCR.00000000001679

- 419 12. Qaseem A, Etxeandia-Ikobaltzeta I, Lin JS, et al. Diagnosis and Management of Acute
- 420 Left-Sided Colonic Diverticulitis: A Clinical Guideline From the American College of
- 421 Physicians. Ann Intern Med. 2022;175(3):399-415. doi:10.7326/M21-2710
- 422 13. Garfinkle R, Sabboobeh S, Demian M, Barkun A, Boutros M; Management of
- 423 Uncomplicated Diverticulitis (MUD) Collaborative. Patient and Physician Preferences
- 424 for Antibiotics in Acute Uncomplicated Diverticulitis: A Delphi Consensus Process to
- 425 Generate Noninferiority Margins. *Dis Colon Rectum*. 2021;64(1):119-127.
- 426 doi:10.1097/DCR.00000000001815
- 427 14. Saunders B, Sim J, Kingstone T, et al. Saturation in qualitative research: exploring its
- 428 conceptualization and operationalization. *Qual Quant*. 2018;52(4):1893-1907.
- 429 doi:10.1007/s11135-017-0574-8
- 430 15. Vanderbilt University Medical Center (2023). *Vanderbilt University Qualitative*
- 431 *Research Core.* Vanderbilt Institute for Medicine and Public Health. Retrieved May 3,
- 432 2023, from <u>https://www.vumc.org/hsr/qualitative-research-core</u>
- 433 16. Chun Tie Y, Birks M, Francis K. Grounded theory research: A design framework for
- 434 novice researchers. *SAGE Open Med*. 2019;7:2050312118822927. Published 2019 Jan 2.
- doi:10.1177/2050312118822927

436 17. Green J, Willis K, Hughes E, et al. Generating best evidence from qualitative res

- the role of data analysis. *Aust N Z J Public Health*. 2007;31(6):545-550.
- 438 doi:10.1111/j.1753-6405.2007.00141.x
- 439 18. O'Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting
- qualitative research: a synthesis of recommendations. *Acad Med.* 2014;89(9):1245-1251.
- 441 doi:10.1097/ACM.00000000000388
- 442 19. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic
- 443 data capture (REDCap)--a metadata-driven methodology and workflow process for
- 444 providing translational research informatics support. J Biomed Inform. 2009;42(2):377-
- 445 381. doi:10.1016/j.jbi.2008.08.010
- 20. Ndjaboue R, Chipenda Dansokho S, Boudreault B, et al. Patients' perspectives on how to
 improve diabetes care and self-management: qualitative study. *BMJ Open*.
- 448 2020;10(4):e032762. Published 2020 Apr 29. doi:10.1136/bmjopen-2019-032762
- 449 21. Moorcraft SY, Marriott C, Peckitt C, et al. Patients' willingness to participate in clinical
- 450 trials and their views on aspects of cancer research: results of a prospective patient
- 451 survey. *Trials*. 2016;17:17. Published 2016 Jan 9. doi:10.1186/s13063-015-1105-3
- 452 22. Ferrell B, Williams AC, Borneman T, Chung V, Smith TJ. Clinical Trials: Understanding
- 453 Patient Perspectives and Beliefs About Treatment. *Clin J Oncol Nurs*. 2019;23(6):592-
- 454 598. doi:10.1188/19.CJON.592-598
- 455 23. CODA Collaborative, Flum DR, Davidson GH, et al. A Randomized Trial Comparing
- 456 Antibiotics with Appendectomy for Appendicitis. *N Engl J Med.* 2020;383(20):1907-
- 457 1919. doi:10.1056/NEJMoa2014320


459 Figure Legends

- 460 Table 1. Characteristics of interview participants.
- 461 Table 2. Summary of themes and representative quotes.
- 462 Table 3. Characteristics of survey participants.
- 463 Figure 1. Conceptual model of factors contributing to reluctance or desire to participate.
- 464 Figure 2. Survey participation rate by recruitment method.
- 465 Figure 3. Survey factors represented by times ranked "Most Important," including A, reasons to
- 466 participate in a randomized controlled trial of antibiotics versus placebo, B, factors used to make
- 467 healthcare decisions, and C, feared outcomes of diverticulitis.

Interview Participant Characteristics			
Variable		N (%)	
Age, mean, (SD)		62.4 (13.0)	
Age by Category			
	18-29 years	0 (0)	
	30-49 years	3 (23)	
	50-64 years	5 (38)	
	≥ 65 years	5 (38)	
Sex	Female	8 (62)	
	Male	5 (38)	
Ethnicity	Hispanic or Latino	0 (0)	
	Not Hispanic or Latino	13 (100)	
Race/Ethnicity	White, Non-Hispanic	11 (85)	
	Black or African American	2 (15)	
	Asian	0 (0)	
	More than one race	0 (0)	
Interview Type	In-Person	9 (69)	
	Phone	4 (31)	
Number of	1st episode	5 (38)	
Diverticulitis	2 - 5	4 (30)	
Episodes	6 - 10	2 (15)	
	11 - 20	1 (8)	
	> 20	1 (8)	

Theme	Subtheme	Quotations	
Personal History and Experiences	Antibiotic Effectiveness	With my first episode, I didn't know what it was, and so I had delayed treatment, so it got extremely infected at a bad abscess And then after that, then I realized that immediate treatment was important. So every time I'd have the symptoms, I would go to the ER as soon as possiblefrom my experience, catching it as early as possible was critical because delayed treatment clearly, in my experience, made it much worse. (Participant 5)	
	Antibiotic Inefficacy	I've had so many episodes and found that [antibiotics] really didn't help. And now my interpretation was that I didn't instantly get better. I got only got better with time as the inflammation settled down. That's my interpretation. (Participant D)	
	Known provider	I would rely on my doctor if he told me that this is a situation that can be alleviated through pain management and some other medication or no medication. (Participant 7)	
Provider Opinion	ED provider	I guess I'm just kind of going on what [the ED doctor] said. If his recommendation was the antibiotic, then I think that would be what I would do. If he said, you can take this or not, and it's going to be the same outcome, I don't know. That might change it if he had said something else. (Participant 6)	
	General medical community	I mean, I take it when they tell me I need it and I go blindlysee, as we all do, maybe. (Participant 9)	
Observation Hesitancy	on Hesitancy That would be my number one concern is what if it doesn't work? How long on have to stay in pain before we can go back to what works? (Participant 5)		
Avoiding antibiotics in the future	Antibiotic hesitancy	I don't ever like to take an antibiotic unless I have to. Okay. Now I'm taking one drug right now that I I have to take, but I take it, and it has had side effects. So as long as I've been on it, and it's called oh gosh And when I first got on it, I had such severe diarrhea, I couldn't leave the house about three or four hours. (Participant C)	
	Healthcare hesitancy	I used to be involved in the fitness industry and there was a lot of people that were my associates that were very into nutrition, and they believed in healing yourself through healthy eating and exercise and didn't like medication So I think we overdo it and I think we damage our immune systems. (Participant 1)	
Public Impact	Helping Others	I think research is research and as we progress, medicine progresses. So I think whatever needs to be done to, for the betterment of everyone, is what needs to be done. (Participant 8)	
	Advancing public knowledge	I mean, on one hand I want to participate in anything it's going to help advance treatment. (Participant 2)	


	rvey Participant Characteristics	
Variable	N (%)	
Age, mean, (SD)	57.9 (13.3)	
Age by Category	18-29 years	3 (1.4)
	30-49 years	55 (25.2
	50-64 years	68 (31.2)
	≥ 65 years	81 (37.2)
Sex	Female	135 (61.9)
	Male	77 (35.3)
	Other/Prefer not to say	2 (0.9)
	Not reported	4 (1.8)
Ethnicity	Hispanic or Latino	12 (5.5)
	Not Hispanic or Latino	191 (87.6)
	Unknown	3 (1.4)
	Not reported	12 (5.5)
Race/Ethnicity	White, Non-Hispanic	152 (69.7)
	Black or African American	9 (4.1)
	Asian	1 (0.5)
	More than one race	4 (1.8)
	Not reported	31 (14.2)
Recruitment Site	ResearchMatch	21 (14)
	MHAV	146 (67)
	Facebook	4 (3)
	Reddit	41 (27)
Number of	1 - 5	172 (78.9)
Diverticulitis	6 - 10	32 (14.7)
Episodes	11 - 20	10 (4.6)
	> 20	2 (0.9)





TRUST IN THE GENERAL MEDICAL COMMUNITY

ADVANCING PUBLIC KNOWLEDGE


Reasons to participate














A